FDA Piloting Oncology Supplement Review Using Only Data Summaries
This article was originally published in The Pink Sheet Daily
Advantages could be shorter review times and expanded labels, but there are concerns about no global regulator having access to full patient-level data.
You may also be interested in...
But the U.S. FDA still cannot force brand firms to provide products for bioequivalence testing, which may limit the policy’s ability to remove a barrier that generic firms allege some NDA sponsors use to block competition.
New claim for platinum-resistant recurrent disease based on a median 3.4-month improvement in progression-free survival – with favorable trends in overall survival, overall response rate and duration of response – confirms agency’s willingness to entertain a progression endpoint in this tumor type.
Both sides may agree to overlook “areas of divergence” if they don’t appear significant.